Cynosure acquisition positive, says Maxim After Cynosure (CYNO) agreed to buy Palomar Medical (PMTI), Maxim thinks the deal will be positive over time for Cynosure, as it believes the deal should increase the company's revenue growth. The firm, however, warns that Cynosure's stock could drop in the short-term. Maxim maintains a Buy rating on Cynosure.
News For CYNO;PMTI From The Last 14 Days
Check below for free stories on CYNO;PMTI the last two weeks.